ZNTL

Zentalis Pharmaceuticals, Inc.

Biotechnology · Biotechnology

$166.32 sample

+1.38 (+0.84%) 1D

Market cap

$166.6B

Price as of

2026-10-04

Latest filing

8-K · 2026-09-25

Alerts

8

Price$166.32 +1.40% 3M daily closessample

180.73164.03

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 25SEC8-K filed: material event
Sep 18INSInsider sell: Chief Financial Officer
Sep 11INSInsider sell: 10% owner
Sep 02INSInsider sell: Chief Executive Officer
Aug 27SEC8-K filed: material event
Aug 21INSInsider sell: 10% owner
Aug 14INSInsider sell: Director
Aug 07INSInsider buy: General Counsel

Sign up to see the real ZNTL record →

Company facts

SEC EDGAR registration

Name: Zentalis Pharmaceuticals, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: -9sample, -100 to +100
Reporting currency: USD

Who is positioning in ZNTL

sample

Insiders: 8 insider transactions over 90 days, net selling, $63.0M
Congress: 3 members traded over 90 days
Institutions · 13F: 9 funds hold $2.1B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$6.1B +14.9% y/y

Q4 2024Q3 2026

Inventory$3.6B +5.8% y/y

Q4 2024Q3 2026

Accounts receivable$2.6B +2.1% y/y

Q4 2024Q3 2026

Total debt$7.5B +11.9% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $118.3B +14.4% 3M
Sample peer B: $25.8B +4.6% 3M
Sample peer C: $147.9B -7.8% 3M
Sample peer D: $27.0B +7.0% 3M
Sample peer E: $60.7B +3.6% 3M